Literature DB >> 8000721

Antiemetic treatment for cancer chemotherapy: problems and progress.

R J Gralla.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8000721     DOI: 10.1007/BF00365576

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


× No keyword cloud information.
  7 in total

Review 1.  Costs and benefits of antiemetic therapy.

Authors:  M S Aapro
Journal:  Support Care Cancer       Date:  1994-09       Impact factor: 3.603

Review 2.  Are there differences among the serotonin antagonists?

Authors:  M Tonato; F Roila; A Del Favero
Journal:  Support Care Cancer       Date:  1994-09       Impact factor: 3.603

Review 3.  Costs and benefits of outpatient therapy.

Authors:  E B Rubenstein
Journal:  Support Care Cancer       Date:  1994-09       Impact factor: 3.603

Review 4.  Delayed emesis following anticancer chemotherapy.

Authors:  M G Kris; K M Pisters; L Hinkley
Journal:  Support Care Cancer       Date:  1994-09       Impact factor: 3.603

Review 5.  Treatment of chemotherapy-induced emesis in the 1990s: impact of the 5-HT3 receptor antagonists.

Authors:  P J Hesketh
Journal:  Support Care Cancer       Date:  1994-09       Impact factor: 3.603

Review 6.  Future of the management of emesis.

Authors:  S M Grunberg
Journal:  Support Care Cancer       Date:  1994-09       Impact factor: 3.603

Review 7.  Antiemetics in children receiving cancer chemotherapy.

Authors:  A L Billett; S E Sallan
Journal:  Support Care Cancer       Date:  1994-09       Impact factor: 3.603

  7 in total
  1 in total

1.  Incidence of chemotherapy-induced nausea and vomiting in Taiwan: physicians' and nurses' estimation vs. patients' reported outcomes.

Authors:  Chi-Ting Liau; Nei-Min Chu; Hsueh-Erh Liu; Robert Deuson; Jade Lien; Jen-Shi Chen
Journal:  Support Care Cancer       Date:  2005-03-16       Impact factor: 3.603

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.